18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging

被引:30
作者
Vidal, Benjamin [1 ]
Fieux, Sylvain [1 ]
Colom, Matthieu [1 ]
Billard, Thierry [2 ]
Bouillot, Caroline [3 ]
Barret, Olivier [4 ]
Constantinescu, Cristian [4 ]
Tamagnan, Gilles [4 ]
Newman-Tancredi, Adrian [5 ]
Zimmer, Luc [1 ,3 ]
机构
[1] Univ Claude Bernard Lyon 1, CNRS, INSERM, Lyon Neurosci Res Ctr, Lyon, France
[2] Univ Claude Bernard Lyon 1, CNRS, Inst Chem & Biochem, Villeurbanne, France
[3] Hosp Civils Lyon, CERMEP Imaging Platform, 59 Blvd Pinel, F-69003 Lyon, France
[4] Mol NeuroImaging, New Haven, CT USA
[5] Neurolixis Inc, Dana Point, CA USA
关键词
Serotonin 1A receptor; PET tracer; Agonist; Rat; Cat; Primate; POSITRON-EMISSION-TOMOGRAPHY; DOPA-INDUCED DYSKINESIA; IN-VIVO EVALUATION; ALZHEIMERS-DISEASE; HUMAN CEREBELLUM; REFERENCE REGION; ENDOGENOUS; 5-HT; CA2+ RESPONSES; BINDING SITES; G-PROTEINS;
D O I
10.1007/s00429-018-1672-7
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Serotonin 1A receptors are known to play an important role in many psychiatric and neurodegenerative disorders. Currently, all available 5-HT1A receptor PET radiopharmaceuticals that are radiolabeled with fluorine-18 are antagonists. As agonists bind preferentially to the high-affinity state of receptors, it would be of great interest to develop agonist radioligands which could provide a measure of the functional 5-HT1A receptors in pathophysiological processes. The 5-HT1A receptor agonist candidates we recently proposed had promising in vitro properties but were not optimal in terms of PET imaging. F13640, a.k.a befiradol or NLX-112, is a 5-HT1A receptor agonist with a high affinity (Ki = 1 nM) and a high selectivity that would be suitable for a potential PET radiopharmaceutical. With propose here the first preclinical evaluation of F-18-F13640. F-18-F13640's nitro-precursor was synthesized and radiolabeled via a fluoro-nucleophilic substitution. Its radiopharmacological characterization included autoradiographic studies, metabolic studies, and in vivo PET scans in rat, cat and non-human primate. Some of the results were compared with the radiotracer F-18-MPPF, a 5-HT1A receptor antagonist. The radiochemical purity of F-18-F13640 was > 98%. In vitro binding pattern was consistent with the 5-HT1A receptor distribution. Metabolic studies revealed that the radiotracer rapidly entered the brain and led to few brain radiometabolites. Although F-18-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors. Preliminary studies also suggest a high sensitivity of F-18-F13640 to endogenous serotonin release. F-18-F13640 has suitable characteristics for probing in vitro and in vivo the 5-HT1A receptors in high-affinity state. Quantification analyses with kinetic modeling are in progress to prepare the first-in-man study of F-18-F13640.
引用
收藏
页码:2973 / 2988
页数:16
相关论文
共 45 条
[1]   5-HT1A Receptor-Mediated Autoinhibition and the Control of Serotonergic Cell Firing [J].
Andrade, Rodrigo ;
Huereca, Daniel ;
Lyons, Joseph G. ;
Andrade, Elaine M. ;
McGregor, Kelly M. .
ACS CHEMICAL NEUROSCIENCE, 2015, 6 (07) :1110-1115
[2]   The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders [J].
Avissar, S ;
Schreiber, G .
CLINICA CHIMICA ACTA, 2006, 366 (1-2) :37-47
[3]   A comparison of in vivo and in vitro neuroimaging of 5-HT1A receptor binding sites in the cat brain [J].
Aznavour, N ;
Rbah, L ;
Léger, L ;
Buda, C ;
Sastre, JP ;
Imhof, A ;
Charnay, Y ;
Zimmer, L .
JOURNAL OF CHEMICAL NEUROANATOMY, 2006, 31 (03) :226-232
[4]   A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment [J].
Bantick, RA ;
Montgomery, AJ ;
Bench, CJ ;
Choudhry, T ;
Malek, N ;
McKenna, PJ ;
Quested, DJ ;
Deakin, JFW ;
Grasby, PM .
JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) :346-354
[5]   Occupancy of agonist drugs at the 5-HT1A receptor [J].
Bantick, RA ;
Rabiner, EA ;
Hirani, E ;
de Vries, MH ;
Hume, SP ;
Grasby, PM .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (05) :847-859
[6]   A Postmortem Study to Compare Agonist and Antagonist 5-HT1A Receptor-binding Sites in Alzheimer's Disease [J].
Becker, Guillaume ;
Streichenberger, Nathalie ;
Billard, Thierry ;
Newman-Tancredi, Adrian ;
Zimmer, Luc .
CNS NEUROSCIENCE & THERAPEUTICS, 2014, 20 (10) :930-934
[7]   Contribution of the Striatum to the Effects of 5-HT1A Receptor Stimulation in L-DOPA-treated Hemiparkinsonian Rats [J].
Bishop, Christopher ;
Krolewski, David M. ;
Eskow, Karen L. ;
Barnum, Christopher J. ;
Dupre, Kristin B. ;
Deak, Terrence ;
Walker, Paul D. .
JOURNAL OF NEUROSCIENCE RESEARCH, 2009, 87 (07) :1645-1658
[8]   Large-amplitude 5-HT1A receptor activation:: a new mechanism of profound, central analgesia [J].
Colpaert, FC ;
Tarayre, JP ;
Koek, W ;
Pauwels, PJ ;
Bardin, L ;
Xu, XJ ;
Wiesenfeld-Hallin, Z ;
Cosi, C ;
Carilla-Durand, E ;
Assié, MB ;
Vacher, B .
NEUROPHARMACOLOGY, 2002, 43 (06) :945-958
[9]   Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF]binding:: A continuous infusion PET study in conscious monkeys [J].
De Haes, JIU ;
Harada, N ;
Elsinga, PH ;
Maguire, RP ;
Tsukada, H .
SYNAPSE, 2006, 59 (01) :18-26
[10]   Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands [J].
Ganz, Melanie ;
Feng, Ling ;
Hansen, Hanne Demant ;
Beliveau, Vincent ;
Svarer, Claus ;
Knudsen, Gitte M. ;
Greve, Douglas N. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 (09) :3243-3252